| Assessment Status | Rapid Review Complete |
| HTA ID | 26012 |
| Drug | Durvalumab |
| Brand | Imfinzi® |
| Indication | Durvalumab (Imfinzi®) is indicated in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable non-small cell lung cancer at high risk of recurrence and no EGFR mutations or ALK. |
| Assessment Process | |
| Rapid review commissioned | 13/03/2026 |
| Rapid review completed | 22/04/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab for this indication compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here